Table 1 Baseline characteristics of participants by treatment allocation to ferric carboxymaltose or iron sucrose
Ferric carboxymaltose (n = 22) | Iron sucrose (n = 20) | P | |
|---|---|---|---|
Age | 70.9 (66.7–76.8) | 75.1 (56.1–79.8) | 0.58 |
Male sex | 16 (73%) | 14 (70%) | 0.85 |
Diabetes | 6 (27%) | 9 (45%) | 0.23 |
Cardiovascular disease | 14 (64%) | 15 (75%) | 0.43 |
History of parathyroidectomy | 1 (5%) | 1 (5%) | 0.95 |
Cause of ESKD | 0.82 | ||
Diabetes | 5 (23%) | 6 (30%) | |
Glomerulonephritis | 2 (9%) | 2 (10%) | |
Vascular | 3 (14%) | 4 (20%) | |
Other | 12 (55%) | 8 (40%) | |
Haemodialysis (hr per week) | 13.5 ± 1.5 | 13.2 ± 1.6 | 0.52 |
URR (%) | 77.6 ± 5.8 | 75.3 ± 6.4 | 0.23 |
Dialysis vintage (months) | 44.3 (21.7–76.6) | 34.6 (18.9–64.6) | 0.35 |
Dry weight (kg) | 76.9 ± 15.8 | 76.8 ± 15.0 | 0.99 |
Urine volume ≥500 mL/day | 7 (32%) | 9 (45%) | 0.38 |
BMI (kg/m2) | 26.5 ± 4.2 | 27.8 ± 5.4 | 0.41 |
SBP (post-dialysis) | 130.0 ± 20.0 | 130.8 ± 24.9 | 0.91 |
DBP (post-dialysis) | 64.0 ± 14.2 | 59.0 ± 16.0 | 0.29 |
Medications | |||
ESA (epoetin-β equivalent, U/week) | 3800 (0–5000) | 2000 (0–5800) | 0.62 |
Receiving any ESA | 16 (73%) | 11 (55%) | 0.23 |
1,25(OH2) Vit D | 12 (55%) | 8 (40%) | 0.35 |
25(OH) Vit D | 9 (41%) | 6 (30%) | 0.46 |
Cinacalcet | 12 (55%) | 7 (35%) | 0.20 |
Calcium carbonate (500 mg/ 600 mg) | 13 (59%) | 9 (45%) | 0.36 |
Lanthanum | 11 (50%) | 9 (45%) | 0.75 |
Sevelamer | 7 (32%) | 8 (40%) | 0.58 |
Multiple binders | 10 (45%) | 6 (30%) | 0.30 |